FBXO48 inhibitors are a class of chemical compounds that specifically target and inhibit the function of the F-box only protein 48 (FBXO48), a member of the F-box protein family. FBXO proteins are part of the ubiquitin-proteasome system, where they function as substrate recognition components of SCF (Skp1-Cullin-F-box) E3 ubiquitin ligase complexes. These complexes mediate the ubiquitination and subsequent proteasomal degradation of target proteins, playing a critical role in various cellular processes, including cell cycle regulation, signal transduction, and protein homeostasis. FBXO48, like other F-box proteins, interacts with Skp1 through its F-box domain and recruits specific substrates for ubiquitination through other domains or regions of the protein. By inhibiting FBXO48, these compounds can interfere with the ubiquitination of particular substrates that are otherwise regulated by FBXO48-mediated degradation.
The inhibition of FBXO48 can lead to the stabilization and accumulation of its substrates, potentially altering intracellular signaling pathways and protein turnover. FBXO48 inhibitors may vary in their mechanisms of action, from small molecules that directly bind to and inhibit FBXO48 to compounds that disrupt its interaction with other components of the SCF complex. Structural studies of FBXO48 and its binding partners are essential for the design of specific inhibitors, as the F-box domain and substrate recognition regions present key targets for modulating the protein's activity. Research into FBXO48 inhibitors contributes to a broader understanding of the regulatory role that FBXO48 plays in cellular dynamics, offering insights into how selective modulation of ubiquitin ligase activity affects various biological pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
Inhibits the NEDD8-activating enzyme, suppressing cullin neddylation and possibly affecting SCF complex function involving FBXO48. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
Inhibits the ubiquitin-activating enzyme E1, potentially diminishing ubiquitin conjugation and affecting FBXO48 functions. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor that can increase the levels of ubiquitinated proteins, potentially impacting proteins regulated by FBXO48. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that may lead to the accumulation of FBXO48 substrates, influencing its regulatory roles. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Modulates the degradation of specific transcription factors, potentially altering FBXO48-mediated ubiquitination processes. | ||||||
CC-122 | 1015474-32-4 | sc-507488 | 5 mg | $420.00 | ||
A cereblon modulator which can change the substrate specificity of E3 ligases, possibly affecting FBXO48 activity. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Influences cellular differentiation processes, which may involve modulation of proteins ubiquitinated by FBXO48. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
A proteasome inhibitor that can lead to increased levels of proteins including potential substrates of FBXO48. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
A specific proteasome inhibitor, may indirectly affect the turnover of FBXO48 substrates. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Another proteasome inhibitor that could lead to altered levels of FBXO48 substrates, affecting its function. | ||||||